Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650 | Zymfentra® (subcutaneous formulation)
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class:
Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [5]. Biosimilars:
View more information in the IUPHAR Pharmacology Education Project: infliximab |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (1998), EMA (1999)) |
International Nonproprietary Names | |
INN number | INN |
7602 | infliximab |
Synonyms |
cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650 | Zymfentra® (subcutaneous formulation) |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 156 |
Other databases | |
GtoPdb PubChem SID | 178101701 |
Immunopaedia Search | infliximab |
PubChem SID | 178101701 |
Search PubMed clinical trials | infliximab |
Search PubMed titles | infliximab |
Search PubMed titles/abstracts | infliximab |
Wikipedia | Infliximab |